Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A. Martinez Chanza N, et al. Among authors: seront e. BMC Cancer. 2021 Dec 2;21(1):1292. doi: 10.1186/s12885-021-08990-3. BMC Cancer. 2021. PMID: 34856936 Free PMC article. Clinical Trial.
A case report of sirolimus use in early fetal management of lymphatic malformation.
Seront E, Biard JM, Van Damme A, Revencu N, Lengelé B, Schmitz S, de Toeuf C, Clapuyt P, Veyckemans F, Prégardien C, Vikkula M, Bernard P, Boon LM. Seront E, et al. Nat Cardiovasc Res. 2023 Jun;2(6):595-599. doi: 10.1038/s44161-023-00280-4. Epub 2023 Jun 1. Nat Cardiovasc Res. 2023. PMID: 39195878
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Seront E, et al. Ann Oncol. 2012 Oct;23(10):2663-2670. doi: 10.1093/annonc/mds057. Epub 2012 Apr 3. Ann Oncol. 2012. PMID: 22473592 Free article. Clinical Trial.
Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E, Rottey S, Filleul B, Glorieux P, Goeminne JC, Verschaeve V, Vandenbulcke JM, Sautois B, Boegner P, Gillain A, van Maanen A, Machiels JP. Seront E, et al. BJU Int. 2016 Sep;118(3):408-15. doi: 10.1111/bju.13415. Epub 2016 Feb 11. BJU Int. 2016. PMID: 26779597 Clinical Trial.
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, Rottey S. Machiels JP, et al. Among authors: seront e. Oncologist. 2016 Dec;21(12):1416-e17. doi: 10.1634/theoncologist.2016-0296. Epub 2016 Nov 30. Oncologist. 2016. PMID: 27903924 Free PMC article. Clinical Trial.
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study.
van Marcke C, Honoré N, van der Elst A, Beyaert S, Derouane F, Dumont C, Aboubakar Nana F, Baurain JF, Borbath I, Collard P, Cornélis F, De Cuyper A, Duhoux FP, Filleul B, Galot R, Gizzi M, Mazzeo F, Pieters T, Seront E, Sinapi I, Van den Eynde M, Whenham N, Yombi JC, Scohy A, van Maanen A, Machiels JP. van Marcke C, et al. Among authors: seront e. BMC Cancer. 2021 May 20;21(1):578. doi: 10.1186/s12885-021-08349-8. BMC Cancer. 2021. PMID: 34016086 Free PMC article.
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Hirsch L, et al. Among authors: seront e. JAMA Oncol. 2021 Dec 1;7(12):1815-1823. doi: 10.1001/jamaoncol.2021.4544. JAMA Oncol. 2021. PMID: 34673916 Free PMC article.
76 results